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 INTRODUCTION 
 
        AIDS is a potentially fatal multisystem disease characterized 
by Profound disruption of the Immune system & a tendency for 
various opportunistic infections & neoplasms. 
    AIDS was first recognized in United States of America in the 
summer of 1981. Since then it has emerged as a global pandemic 
health problem of extra ordinary proportions & unprecendented 
emergency. 
        At the end of 2007, 33.2 million people were living with HIV 
as per Joint United Nations Programme on HIV/AIDS. There are 
nearly  5.7 million people infected with HIV in India. 
      Ocular manifestations are seen in 40 – 70 % of HIV patients. It 
can be caused by opportunistic infections, immunological reactions, 
neoplasms & by HIV infection per se. It can affect almost all the 
structures of the eye. 
        Life time cumulative risk of atleast one abnormal ocular lesion 
developing in HIV patient ranges from 52 – 100 % in various 
studies. Some of these manifestations are potentially vision 
threatening. 
 CD4 lymphocyte cells are proved to be a reliable predictor of 
ocular manifestations of HIV infection. Ocular lesions are usually 
seen in the end stages of the disease when the immunity is the lowest 
(low CD4 count). With the introduction of HAART in 1990s, the 
incidence of ocular manifestations has come down. 
     Many a times ocular lesions may be the first clinical presentation 
& can help the clinician to suspect the underlying HIV infection. 
        Ocular lesions can be categorized by the ocular structures 
involved as below 
• Anterior segment manifestations – seen in upto 50% of HIV 
patients 
• Posterior segment manifestations – the most common & the 
most severe vision threatening manifestations seen in > 50% 
of HIV infected patients. HIV microangiopathy is the most 
common lesion followed by CMV retinitis. 
• Ocular adnexal manifestations. 
• Neuro ophthalmic manifestations – seen in 10 – 15 % of HIV 
infected patients. 
• Orbital lesions. 
 Early recognition of ocular lesions will help early institution of 
therapy & there by preventing visual loss. This is of even greater 
significance nowadays, following the introduction of HAART & 
with increased life expectancy of AIDS patients. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 HUMAN IMMUNODEFICIENCY VIRUS 
  HIV is a RNA virus belonging to human Retro virus, 
Lentivirus subfamily. It has a unique reverse transcriptase enzyme. 
HIV 1 & HIV 2 are currently known to infect human beings. In 
India, HIV Type 1c is the commonest type reported, though both 
types exist. 
MORPHOLOGY OF VIRUS: 
       Virus is 120 nm in diameter consisting of an outer envelope, a 
core shell of protein & a cone shaped inner core containing RNA 
genome, reverse transcriptase enzyme & core polypeptides. 
               There are 3 structural genes  
1. ‘gag’ gene ( group antigen) 
2. ‘pol’ gene ( polymerase) 
3.  ‘env’ gene ( envelope antigen) 
Apart from these genes, the virus also contains additional 
regulatory genes like tat, rev, ref, vif, vpr & vpu. 
STAGES OF VIRAL REPLICATION: 
• HIV glycoprotein 120 attaches to the CD 4 receptors on CD4 
cells , activated monocytes & macrophages & glial cells ; 
virus enter these cells 
 • RNA genome of HIV is converted to DNA by reverse 
transcriptase enzyme. 
• Viral DNA then enters the host nucleus & gets incorporated 
into the host cell DNA with the help of endonuclease. 
• Virus components are produced by the host cell. Mature 
viruses burst out of the host cell, lysing them, to infect new 
cells Viral turn over is very high upto 10^9 particles every 
1.5 – 2 days. 
ROUTES OF TRANSMISSION: 
            The major routes of transmission are sexual contact, 
parenteral exposure to blood & blood products & vertical 
transmission. 
WHO CLINICAL STAGING OF HIV/AIDS FOR ADULTS & 
ADOLSCENTS, 2006. 
CLINICAL STAGE 1: 
•  Asymptomatic 
• Persistent generalized lymphadenopathy 
CLINICAL STAGE 2: 
• Unexplained weight loss 
• Recurrent respiratory tract infections 
 • Herpes zoster 
• Minor mucocutaneous manifestations 
CLINICAL STAGE 3: 
• Unexplained severe weight loss 
• Chronic diarrhea > 1 month duration 
• Persistent fever > 1 month duration 
• Oral candidiasis 
• Oral hairy leukoplakia 
• Pulmonary tuberculosis 
• Severe bacterial infections  
• Unexplained anemia 
CLINICAL STAGE 4: 
• HIV wasting syndrome 
• Pneumocystis pneumonia 
• Esophageal candidiasis 
• Cytomegalovirus infection 
• CNS toxoplasmosis 
• HIV encephalopathy 
• Extra pulmonary tuberculosis 
 • Kaposi sarcoma 
• Lymphoma 
 
CDC REVISED CLASSIFICATION OF HIV DISEASE – 1993 
 
Absolute CD4 
count cells/cu 
mm 
A 
Asymptomatic/ 
PGL/ acute 
seroconversion 
illness 
B 
HIV related 
conditions not 
included in A or 
C 
C 
Clinical 
conditions 
listed in AIDS 
surveillance 
case definition 
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        A1 
        A2 
        A3 
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 OCULAR MANIFESTATIONS OF HIV 
 
                  Ocular involvement in AIDS is very common & includes 
various clinical presentations. 
             The first report of the ocular manifestation in AIDS was 
done by Holland et al in 1982. In India, it was reported by J.Biswas 
et al in 1995. 
             In general CD4 count has been used to predict the onset of 
certain ocular infections in HIV patients. 
CD4 COUNT 
cells/ cu mm 
OCULAR MANIFESTATIONS 
<500 
<250 
<100 
 
Kaposi sarcoma,lymphoma, TB  
Pneumocystis, toxoplasmosis  
Retinal/conjuctival microvasculopathy, VZ retinitis, 
CMV retinitis, MAC infections, cryptococcosis, 
microsporidiosis, HIV encephalopathy, progressive 
multifocal leukoencephalopathy 
 
OCULAR ADNEXAL MANIFESTATIONS 
Adnexal manifestations are seen in 25% of HIV patients & it 
can be a sign of severe immunosuppression. It includes 
              Herpes zoster ophthalmicus 
              Conjunctival microvasculopathy 
             Conjunctival OSSN 
             Kaposi sarcoma 
HERPES ZOSTER OPHTHALMICUS: 
        It is a painful vesiculo bullous dermatitis resulting from the 
reactivation of the latent varicella zoster virus in the ophthalmic 
division of the trigeminal nerve. 
        It is seen in 5-15% of HIV patients. Any patient younger than 
50 years of age presenting with HZO should  be suspected to have 
underlying immunosuppression like HIV. 
      In HIV patients, HZO have prolonged & severe course with a 
higher rate of painful sight threatening complications & increased 
incidence of post herpetic neuralgia. It may also occur bilaterally & 
without associated skin lesions. 
        HZO is associated with conjunctivitis, keratitis, scleritis, 
blepharitis, uveitis, retinitis , encephalitis, hemorrhagic hypopyon. 
         Tissue damage is mediated through occlusive vasculitis. 
         The relative risk of HZO in HIV patients is 6.6: 1. 
 
 
 TREATMENT: 
INDUCTION DOSE:   
I.V. Acyclovir 10mg/kg body weight TID – 7 days  
MAINTENANCE DOSE:  
oral acyclovir 800mg 5 times a day for atleast 3-5 weeks. 
Other drugs :  famciclovir, I.V. foscarnet 
 LID INFECTIONS 
    Often severe & recurrent blepharitis, stye & lid ulceration can 
occur. 
TREATMENT:  lid hygiene, antibiotics 
MOLLUSCUM CONTAGIOSUM 
       Highly contagious infection caused by DNA pox virus. 
       The eyelid is involved in 5% o HIV infected patients. In these 
patients, they are multiple, rapidly growing, bilateral, confluent & 
more prone for secondary infections. They tend to recur after 
removal. 
       The virus particles may release into tears & cause toxic 
keratoconjunctivitis. 
TREATMENT:  
Cryotherapy with podophyllotoxin cream as an adjunct & 
excision. 
 CONJUNCTIVAL MICROVASCULOPATHY 
           An asymptomatic vascular changes including segmental 
vascular dilatation & narrowing, microaneurysm, comma shaped 
vascular fragments & sludging of blood columns. 
           It is seen in 70 – 80% of HIV patients.  
Specific etiology is not known. However increased plasma 
viscosity & immune complex deposition related to HIV or the direct 
infection of HIV in the endothelium may be the cause.  
 No treatment required. 
CONJUNCTIVAL OSSN 
       It is usually seen in old age  > 70 years and rarely seen in 
normal persons. 
           In HIV patients, the risk of developing OSSN increases by 
10-13 fold & occurs in young age. It constitutes the third most 
common neoplasm associated with HIV. It bears no correlation with 
CD4 count. 
            Hypothesis proposed for etiology: 
1. generalized depression of immune surveillance with 
severe immunosuppression 
2. coinfection with HPV 16 & 18. 
 Usually presents as pink papillomatous mass with feeder 
vessels in the limbus. 
TREATMENT: 
Local excision with 2-3 mm safety margin & underlying 
scleral resection 
Adjunctive: cryotherapy to the conjunctival margins, 
brachytherapy, topical chemotherapy ( mitimycin c, 5 – fluorouracil, 
IFN α 2B) 
Enucleation , exenteration can be done if the tumour is advanced. 
KAPOSI SARCOMA 
It is a highly vascularised, painless mesenchymal tumour that 
affect skin & mucous membrane. Propable etiology may be due to 
infection of human herpes virus – 8.  
Conjunctival  KS is seen in 10 – 20% in HIV patients . But in 
India it is very rare, because of low incidence of HHV – 8. 
TREATMENT : radiation therapy 
Excision with intralesional vinblastine. 
 
 
 
 ANTERIOR SEGMENT MANIFESTATIONS: 
       >50% of HIV patients have anterior segment manifestations. 
It includes   
  1. Keratitis 
           2. Keratoconjunctivitis sicca 
           3. Iridocyclitis 
KERATOCONJUNCTIVITIS SICCA: 
     Results from deficiency of any tear film layer; usually seen in the 
late stage. 
     It is seen in 10 -20 % of HIV infected patients. Etiology is related 
to HIV mediated inflammation & damage to the accessory glands & 
to the direct effect of HIV virus itself on conjunctiva. 
TREATMENT:  
Lubricants & eye ointments                                              
KERATITIS: 
VIRAL: 
Herpes is the most common cause of infectious keratitis. In 
HIV patients, they tend to have a longer, more severe course. They 
recur more often & resistant to treatment. 
   HSV – predilection for peripheral cornea & may cause painful 
corneal ulceration. In HIV patients, since the T cell immunity is low, 
 HSV stromal disease occur infrequently.   HZV – usually associated 
with HZO iritis & increase in IOP may occur. 
TREATMENT:  Topical & systemic antiviral agents.  
BACTERIAL:  
Frequency not increased but generally more severe in HIV 
patients.  It may occur bilaterally, involve multiple pathogens & 
carry a higher risk of perforation. 
           Ocular flora in HIV patients is not different from that of 
general population, but the risk of infection with the normal flora is 
high in severely immuno suppressed individuals. 
 MICROSPORIDIA: 
          Cause multiple diffuse punctuate epithelial keratopathy & 
follicular conjunctivitis. Massom trichrome or giemsa stain can be 
used for diagnosis. 
TREATMENT: topical fumagilin, oral albendazole, oral 
itraconazole. 
IRIDOCYCLITIS 
It is rarely associated with HIV disease. It is usually associated 
with retinal or choroidal infection with opportunistic infections such 
as CMV, HSV, HZV, TB , etc. 
       Rifabutin & cidofovir may induce iritis. 
Immune recovery uveitis in CMV infected patients on HAART 
therapy. 
POSTERIOR SEGMENT MANIFESTATIONS 
          Seen in more than 50% of HIV infected patients. 
It includes 
             1. non infectious – HIV microangiopathy & 
             2. infectious 
These lesions can potentially affect the vision, if not treated 
early. 
HIV MICROANGIOPATHY: 
The most common ocular lesion seen in 50-70% of HIV 
infected patients. The lesion includes cotton wool spots, 
hemorrhages & microaneurysm, which are generally asymptomatic 
& transient. BRVO, BRAO & ischemic maculopathy may occur. 
Etiology may be due to 
                    Increased plasma viscosity & fibrinogen levels 
                    Circulating immune complexes 
                    Infectious damage to the endothelium 
           No treatment required. HAART decreases the prevalence of 
microangiopathy. 
 CMV RETINITIS: 
  The most common opportunistic intra ocular infection in HIV 
patients seen in 15 – 40% .It occurs when the CD4 count is <100 
cells / cu mm. 
Clinically present as three forms: 
1. perivascular fluffy white lesion with many scattered 
hemorrhages. 
2. more granular lesion with few hemorrhages with central area 
of atrophic retina. 
3. frosted branch angitis – rare 
These lesions expand in brush fire pattern. Anterior spill over 
uveitis may occur with fine stellate KPs. 
   Complications include retinal detachment & optic nerve 
involvement. 
CMV IN HAART ERA: 
After the introduction of HAART,  
¾ the incidence of CMV retinitis has decreased by 75%,  
¾ the risk of vision loss is lower,  
¾ the risk of RD is 60% less & the survival increased by > 1 
year.  
 Patients treated with HAART with sustained CD4 count 
elevation of >100 cells/cu mm for atleast  3-6 months & with well 
healed CMV retinitis inactive for 3-4 months can be given a trial of 
withdrawal of CMV therapy. 
IMMUNE RECOVERY UVEITIS: 
It is an intra ocular inflammation caused by the reconstituted 
immune system with HAART therapy in response to the persistence 
of CMV antigen. 
It may present as anterior uveitis, vitritis, papillitis & macular 
edema. Complications include cataract, CME & epiretinal membrane 
formation. 
TREATMENT :  topical & periocular steroids 
 
 
 
 
 
 
 
 
  
TREATMENT OF CMV RETINITIS: 
 
ANTI CMV 
DRUG 
INDUCTION MAINTENANC
E 
SIDE EFFECTS 
Ganciclovir 
Oral 
Intravenous 
intravitreal 
 
 
Not used 
5mg/kgBDx2wks
200-2000 mcg 
/0.1 ml 
 
1gm TID 
5mg/ kg daily 
Weekly once 
Neutropenia, 
thrombocytopenia
, anemia, 
nephrotoxicity 
Valganciclovir 
oral 
 
900mgX2wks 
 
 
900mg OD 
 
 
Same as above 
Foscarnet 
Intravenous 
 
intravitreal 
 
60mg TID X 3 
wks 
2.4 mg /0.1 ml ; 
twice weekly 
 
90 mg/kg OD 
 
Once a week 
 
Nephroyoxicity, 
electrolyte 
imbalance 
Cidofovir: 
Intravenous 
 
intravitreal 
 
5mg/kg once a 
wk X 2wks 
15 – 20 mcg/0.1 
ml 
 
5mg/kg every 2 
weeks 
Once in 6 wks 
Proteinuria, 
hypotony,iritis, 
neutropenia, 
peripheral 
neuropathy 
fomiversin 330 mcg; 2 doses 
for every 2 
weeks 
2 doses for every 
month 
 
           
GIOD -  Ganciclovir Intraocular Device 
 It is a sustained release drug delivery device that contains 
about 4.5 – 6mg of ganciclovir.  It is surgically placed into the 
vitreous through the pars plana route.  
  
Investigational drugs:   maribavir, tomeglovir 
RD in CMV retinitis is characterized by multiple breaks, so 
vitrectomy with silicon oil injection is the preferred modality of 
treatment. 
TOXOPLASMA RETINOCHOROIDITIS 
         It accounts for 1% of the AIDS related retinal infections. 
The typical ocular presentation is  
     A focus of retinitis adjacent to a pigmented retinochoroiditic scar.  
     Vitritis , spill over anterior uveitis, focal retinal vasculitis are 
associated factors. 
TREATMENT: 
DRUGS DOSAGE 
SCHEDULE 
SIDE EFFECTS 
pyrimethamine 75mg/day X2 days; 
25mg/day X 4 wks 
Bone marrow 
depression, GI 
intolerance, 
teratogenic 
sulfadiazine 2g orally followed by 
1 gm QID X 4 wks 
Renal crystallization, 
skin rash, SJ 
syndrome 
 
 
 
 OCULAR SYPHILIS: 
It is seen in 1-2 % of HIV patients. In HIV patients, ocular 
syphilis is often associated with neurosyphilis. The most common 
presentation is uveitis. Others include retinitis, vasculitis, optic 
neuritis & papilloedema.   Treatment: 12-14 million units /day of IV 
penicillin G – 14 days. 
FUNGAL INFECTIONS: 
          Candida, Cryptococcus, pneumocystis carinii  infection can 
occur. 
NEURO OPHTHALMIC MANIFESTATIONS: 
         Seen in 10-15% of HIV patients. It may be due to direct effect 
of HIV or secondary to opportunistic infection of CNS.  
Cryptococcal meningitis & intracerebral toxoplasma may 
cause papilloedema, optic atrophy & cranial nerve palsies. 
Neurosyphilis, progressive multifocal leukoencephalopathy, CNS 
lymphoma & intra cerebral infection with herpes may also be related 
to neuro phthalmic manifestations. 
ORBITAL MANIFESTATIONS: 
         Uncommon in HIV patients. Orbital lymphoma & orbital 
cellultis due to aspergillus are more common. 
 REVIEW OF LITERATURE 
Kuppermann BD et al (1993) studied the prevalence of CMV 
retinitis & HIV retinopathy in HIV patients. In his study, CMV 
retinitis was seen in 20% patients& HIV retinopathy in 35% . In pts 
with CD4 count < 50cells /cumm, 30% had CMV retinitis & 45% 
had HIV retinopathy. In patients with CD4 count > 50cells /cu mm, 
none of the patients had CMV but 16 % had HIV retinopathy. 
DA Jabs et al (1995) studied the frequency of ocular 
complications in HIV patients . He reported CMV retinitis in 37% of 
HIV patients & HIV retinopathy in 50%. toxoplasma, VZ retinitis, 
pneumocystis choroidopathy seen in < 1%. HZO was seen in 3% of 
patients & in all stages of the disease. NO manifestations were seen 
in 6% of patients secondary to cryptococcal meningitis.   
J Biswas et al (1998) reported CMV retinitis in 24% & HIV 
retinopathy in 19% of cases with ocular manifestations. Optic 
atrophy & RD were attributed to CMV retinitis. Endogenous 
endophthalmitis was seen in 6% of cases. 
DK sahu et al (1999) evaluated the prevalence of ocular 
manifestations in a group of 19 patients with HIV from South India. 
In their report, none of them had conjunctival malignancy & corneal 
 involvement. All 19 patients had posterior segment involvement 
primarily. HIV retinopathy was present in 34%, CMV retinitis in 
39%, HS related ARN & retinitis in 11%, TB choroiditis in 11%, 
while HZ retinitis & presumed P.carinii choroidopathy each were 
observed in 2.5% of eyes. 
Macdonald JC et al (2000) studied the effect of immune 
recovery in HIV patients treated with HAART on CMV retinitis. 
They have reported that in patients treated with HAART, with 
sustained elevation of CD4 count & healed inactive CMV retinitis > 
4 months are likely to remain healed if anti CMV therapy is 
withdrawn. 
J. Biswas et al (2000) reported that the spectrum of ocular 
lesions associated with HIV infection in India is different. The 
prevalence of CMV retinitis & HIV retinopathy is lower in India. 
They reported CMV retinitis in 17% & HIV retinopathy in 15 %. 
Furrer et al (2003) evaluated the prevalence of HIV 
retinopathy. HIV retinopathy was present in 24% & opportunistic 
viral retinitis in 7% of HIV patients. In this study, the 
microangiopathy was associated with higher age & higher viral load 
of HIV rather than related to immunosuppression. 
 Goldberg et al (2005) studied the effectiveness of HAART on 
HIV associated retinopathies. They reported that CMV retinitis 
declined by 80% in the HAART era. The survival also increased 
from 6-10 months to 1 year. Immune recovery uveitis may occur in 
upto 63% of patients with regressed CMV retinitis on HAART. 
Pradyot Biswas et al (2008) studied the ophthalmic 
manifestations in HIV patients in Eastern India. Ophthalmic 
manifestations were found in 29.14%. In that, 64.7% had posterior 
segment manifestations, 23.52% had neuro ophthalmic 
manifestations, 19.60% had anterior segment lesions 15.69 % had 
adnexal lesions. HIV retinopathy was the commonest involving 23 
eyes. CMV retinitis was seen in only 10 eyes. Ophthalmic 
manifestations were less in this study than reported in earlier 
literature in India & abroad. 
Venkatesh et al (2008) studied the ophthalmic manifestations 
of HIV in India in the HAART era in this study, 45% had 
ophthalmic manifestations, the most common being the CMV 
retinitis. HIV retinopathy was seen in 11%, IRU in 5% , ARN in 3%, 
choroiditis in 2%, NO lesions in 12%, complicated cataract in 6%, 
keratouveitis in 1%  & corneal ulcer in 1%. 7% of patients presented 
 with ophthalmic manifestations as the only presenting sign of HIV 
infection. Among those who had ocular manifestations, 50% had 
CD4 count < 100cells /cu mm & 70% had CD4count < 200 cells 
cumm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                                 AIM OF THE STUDY 
 
The aim of this study is to determine the frequency of various 
ocular manifestations in HIV infected patients. 
Objectives : 
¾ To correlate the various ocular manifestations with the CD4 
count 
¾ To study the frequency of various ocular manifestations in 
different age groups 
¾ To study the sex distribution of various manifestations 
¾ To analyse the frequency of occurrence of other systemic 
comorbid conditions. 
¾ To compare and analyse the present study with inference to 
other studies in literature 
¾ To emphasize the importance of early ophthalmic examination 
and frequent follow up on HIV infected patients. 
 
 
 MATERIALS AND METHODS 
SITE OF THE STUDY: 
 The study was carried out in the Department of 
Ophthalmology, Government Rajaji Hospital, Madurai. 
PERIOD OF THE STUDY : 
 The study was conducted from November 2008 to October 
2009. 
INCLUSION CRITERIA : 
1. Patients diagnosed as HIV infected (confirmed by ELISA / 
TRIDOT test) 
2. Patients of all age groups are included. 
EXCLUSION CRITERIA : 
1. Patients not willing to participate in the study 
2. Seriously ill patients who cannot cooperate for 
ophthalmological examination. 
ETHICAL COMMITTEE APPROVAL : 
 The study was submitted for approval of ethical committee 
meeting at Dean’s chamber at Government Rajaji Hospital and 
approval was obtained. 
 
 SAMPLE SIZE:   
         100 patients from both sexes 
DESIGN OF THE STUDY: 
 Cross sectional study (also known as Prevalence study) 
SELECTION OF THE STUDY SUBJECTS : 
 Patients diagnosed as HIV infected attending ophthalmology 
out patient department GRH and those referred from ART centre and 
other departments, fulfilling the inclusion criteria are included in the 
study. 
PROCEDURE OF THE STUDY : 
 Following details were collected from each patient. 
 General symptoms ocular symptoms, past history of 
tuberculosis, treatment history (HAART, prophylaxis treatment). 
Risk factors like sexual promiscuity, sexually transmitted diseases, 
blood transfusion and IV drug abuse are recorded using a master 
chart for each patient. 
 Examination to rule out any systemic illness which includes 
examination of 
¾ Skin and mucosa 
¾ Central nervous system 
 ¾ Respiratory system 
¾ Cardiovascular system 
¾ Respiratory system 
¾ Gastrointestinal tract 
Detailed ophthalmic evaluation : 
¾ Preliminary oblique examination done 
¾ Visual acuity checked with Snellen’s chart 
¾ Anterior segment was examined using slit lamp 
biomicroscopy. 
¾ Dilated fundus examination was done with Direct and indirect 
ophthalmoscopy. 
¾ Findings were noted. Appropriate photographs were also 
taken. 
 
 
 
 
 
 
 
  
 
 
OBSERVATION AND  RESULTS 
 
Total number of patients   - 100 
 No. % 
No. of patients with ocular manifestations 54 54% 
No. of patients with anterior segment 
manifestation 
7 12.9 % 
No. of patients with posterior segment 
manifestations 
17 31.5% 
No. of patients with neuroophthalmic 
manifestations 
4 7.4% 
No. of patients with adnexal manifestations 43 79.62% 
 
 
 
 
 
 
                                              
 
  
Table 1 
AGE DISTRIBUTION 
Age in 
years 
No.of 
cases 
% Ocular 
manifes 
tations 
AS manifes 
tations 
PS manifes 
tations 
Adnexal 
Manifes 
tations 
0 - 10 3 3 0 0 0 0 
11-20 3 3 0 0 0 0 
21-30 32 32 20         
(62.5%) 
1           
(3.1%) 
6       
(18.75%) 
18 
(56.25%) 
31-40 41 41 22          
(53.65%) 
5           
(12.2%) 
6       
(14.63%) 
16 
(39%) 
41-50 18 18 11          
(61%) 
1           
(5.5%) 
5 
(27.7%) 
8 
(44.4%) 
51-60 3 3 33          
(1%) 
0 0 1 
(33.3%) 
>60 0 0 0 0 0 0 
 
 Majority of the patients in this study were in the age group of 
31-40 (40%) and 21-30 (35.5%) corresponding to sexually active 
high risk group.  Nearly 50% of the patients in this group showed 
ocular manifestations. 
 
 
  
 
 
Table 2 
SEX DISTRIBUTION 
Sex No.of 
cases 
% Ocular 
manifestations
AS   
mani 
festations
PS 
manifestations 
Adnexal 
mani 
festations
Male 60 60 32   
(53.3%) 
5   
(8.3%) 
9   
(15%) 
24 
(40%) 
Female 40 40 22 
 (55%) 
2   
 (5%) 
8  
(20%) 
19  
(31.6%) 
 100 100 54 7 17 43 
 
 Males are predominant in number in this study in the ratio of 
1.5 : 1. 
 
 
 
 
 
  
 
 
Table 3 
ASSOCIATED SYSTEMIC INFECTIONS 
Systemic 
infections 
No.of cases % Ophthalmic 
manifestations 
TB         24       24%         14 
Herpes (Oral 
and genital) 
         7        7%         3 
Oral candidiasis         10       10%        5 
Cryptococcal 
meningitis 
        1       1%       1 
  
          Tuberculosis is the most common systemic disease associated 
with HIV infected patients. 
           Others include oral candidiasis and Herpes. 
 
 
 
  
 
 
                                                    Table 4 
              CD4 COUNT & OCULAR MANIFESTATIONS 
                             
CD4 
count 
No.of 
patients / 
% 
No.of pts with 
ocular 
manifestations 
No.of pts with 
AS 
manifestations 
No.of pts with 
PS 
manifestations 
< 100 23(23%) 14 (60.87%) 1 (4.34%) 7 (30.4%) 
100 - 200 30(30%) 16 (53.3%) 1 (3.3%) 4(13.33%) 
200 – 300  19(19%) 11(57.9%) 0 2(10.52%) 
300 – 400 13(13%) 6(46%) 2(15.4%) 1(7.7%) 
≥ 400 15(15%) 7(46.67%) 3(20%) 3(20%) 
Total  100 54 7 17 
 
            Majority of the patients with ocular manifestations had CD4 
count < 100 cells / cumm. 
 
 
 
 
 
  
 
 
Table 5 
ANTERIOR SEGMENT 
AS  Manifestations No of cases 
Iritis 5 
Dry Eye 2 
Keratitis 0 
 
IRITIS 
 1 case associated with CMV retinitis 
 1 case associated with TB Panuvetis 
 1 case associated with toxoplasma 
 2 cases – old with festooned pupil 
 
 
 
 
 
  
 
 
Table 6 
ADNEXAL MANIFESTATIONS 
Adnexal   Manifestations No.of patients % 
Conj microvasculopathy 36 83 
Allergic conjunctivitis  2 4.6 
OSSN 1 2.3 
HZO 1 2.3 
Mollussum of lid 1 2.3 
Blepharitis 1 2.3 
Lacrimal fistula 1 2.3 
ACCO 1 2.3 
 
         Adnexal manifestations were seen in 43 (43%) of HIV infected 
patients. 
 
 
 
                                               
 
                     CONJUNCTIVAL MICROVASCULOPATHY 
 Seen in 36 patients, accounting for 83% of adnexal 
manifestations. 
 19.4% of patients with conjunctival microvasculopathy 
have been associated with retinal microvasculopathy. 
Table - 7 
CD4 COUNT & CONJUCTIVAL MICROVASCULOPATHY 
CD4 Conjunctival  
micro 
vasculopathy 
% HIV microangiography 
seen in pts with 
conjunctival 
microvasculopathy 
<100 9 39.13 4 
100-200 15 50 2 
200-300 8 42.10 0 
300-400 2 15.38 0 
>400 2 13.33 1 
Total 36 36 7 
 
 
 
  
 
 
Table 8 
POSTERIOR SEGMENT MANIFESTATIONS 
Seen in 17(17%) patients  
POSTERIOR SECALENT 
MANIFKCTATIONS 
No  of patients % 
HIV microangiography 10 58 
CMV retinitis 4 23.5 
Toxoplasma retinitis 1 5.9 
TB Panuveitis 1 5.9 
Old choroiditis scar 1 5.9 
 
            HIV microangiopathy was the most common lesion followed 
by CMV retinitis in this study. 
 
 
 
 
  
 
Table 9 
HIV MICROANGIOPATHY 
              Comprises 58% of patients having PS manifestations and is  
the most common PS manifestation. 
                CD 4 count and HIV microangiopathy 
CD4 HIV micro 
angiography 
% Bilateral 
<100 5 21.7 3 
100-200 2 6.7 0 
200-300 1 5.26 0 
300-400 0 0 0 
>400 2 13.33 1 
Total 10  4 
 
          With the decrease in the CD4 count, the incidence of HIV 
microangiopathy increases. 
 
 
  
 
 
Table 10 
AGE DISTRIBUTION OF HIV MICROANGIOPATHY 
Age HIV micro 
angiography
% Bilateral 
0-10 0 0 0 
11-20 0 0 0 
21-30 2 6.25 1 
31-40 4 9.75 0 
41-50 4 22.2 3 
51-60 0 0 0 
>60 0 0 0 
 
            As the age increases, the incidence of HIV microangiopathy 
has also been increased in this study. 
 
 
 
  
 
CMV RETINITIS 
           Seen in 4 (23.5%), patients with posterior segment 
manifestations. 
Table 11 
CD4 Count and CMV retinitis 
CD4 CMV 
retinitis 
% Bilateral ART taking
< 100 1 4.3 1 Yes 
100-200 2 6.7 1 Yes 
200-300 1 5.3 0 Yes 
300-400 0 0 0 0 
> 400 0 0 0 0 
 
            All the patients were on ART and 3 patients had CD4 count 
> 100 cells / cumm. 
            
 
 
  
 
 
NEURO OPHTHALMIC MANIFESTATIONS 
           Seen in 4 patients. Majority were sequelae of CNS lesions. 
 
Table 12 
CD4 Count & Neuro ophthalmic manifestations 
CD4 count No.of 
patients / %
No.of patients 
with ocular 
manifestations 
No.of patients with 
neuro ophthalmic 
manifestations 
< 100 23(23%) 14 (60.87%) 2 (8.7%) 
100 - 200 30(30%) 16 (53.3%) 0 
200 – 300  19(19%) 11(57.9%) 0 
300 – 400 13(13%) 6(46%) 1 (7.7%) 
≥ 400 15(15%) 7(46.67%) 1 (6.67%) 
Total  100 54 4 
 
 
 
 
 
 
  
 
 
Table 13 
HAART & OCULAR MANIFESTATIONS 
 No of 
Patients 
No of patients 
with ocular 
manifestations
AS 
manifes 
tations 
PS 
manifes 
tations 
Neuro ophthal 
manifestations
On 
HAART 
18 
(19%) 
13  
(72%) 
12  
(66.67%)
5  
(27.78%) 
3   
(16.675) 
Not on 
HAART 
82  
(82%) 
41   
(50%) 
36  
(43.9%) 
12  
(14.63%) 
1   
(1.22%) 
 
           Patients on HAART had more ocular manifestations than those 
patients not on HAART.  HAART taking patients would be in the late 
stage of the disease with low CD4 count and so they are more prone for 
infections. 
 
 
 
 
 
 DISCUSSION 
 The incidence of ocular manifestations in HIV infection has 
been reported on various studies to occur upto 100% (Ryan).             
J Biswas et al reported an incidence of  40-70%.  In this study, 
Ocular manifestations are seen in 49% of patients. 
 Adrenal manifestations are most commonly seen in 79.6% of 
patients with ocular manifestations followed by posterior segment 
manifestation seen in 31.5% of patients.  Anterior segment 
manifestations are seen in 13% and neuro ophthalmic manifestations 
in 7.4%. 
 Pradyot Narayan Biswas et al (2008) reported 29.14% of 
ophthalmic manifestations. Of them 64.7% had posterior segment 
lesion, 23.52% had neuroophthalmic manifestations, 19.6% had 
anterior segment lesion 15.69% had adnexal lesion. 
 Venkatesh et al (2008), reported ocular manifestations in 45% 
of patients, CMV retinitis being the most common. 
 The ocular manifestations in HIV infected patients are less 
common in this study than reported in earlier literature in India and 
abroad.  This is supported by the studies of J Biswas et al (2000) & 
Pradyot et al (2008). This may be attributed to the lack of awareness 
 among patients, lack of adequate knowledge among health 
professionals and lack of facilities to look for ophthalmic 
manifestations in HIV infected individuals in India. 
 Majority of patients in this study are in the age group of 20 – 
40 (73%), which is comparable to the WHO estimates (62.39%). 
This is attributed to the fact that this being the sexually active age 
group, the risk of exposure is very high.  The increased awareness of 
the disease and early reporting in this age group can also be a 
contributing factor. 
 The gender incidence in this study is 1.5 : 1 (male : female).  
This male predominance is explained by their high risk of exposure 
due to their nature of work and economic freedom.  According to 
WHO estimates among the adult living with AIDS/HIV 59% are 
males and 41% are females.  In this study, it is 60% and 40% 
respectively which correlates well with the WHO reported incidence. 
 In this study, the most common systemic disease associated 
with HIV / AIDS patients is tuberculosis seen in 24% of patients oral 
candidiasis was seen in 10% and Herpes in 7% of patients. 
Cryptococcal meningitis, AIDS dementia complex, anemia are also 
 seen.  Among tuberculosis patients, ocular manifestations are seen in 
58.3%.  
 CD4 T cell count is an important predictor of immune 
suppression in HIV / AIDS patients. In this study, 11% of patients 
had CD4 < 50 cells / mm3, 23% had CD4 count < 100 cells/mm3 
and 53% had CD4 count < 200 cells / mm3. 
 In this study, 72% of patients show ocular manifestations in 
HIV patients with CD4 count < 50 cells / mm3. In patients with CD4 
count < 100 cells per cumm, 60.87% had ocular manifestations & 
between 100-200, 53.3% had ocular manifestations. Ocular 
manifestations decrease in prevalence with increase in CD4 count. 
 The observation concludes that the CD4 count is inversely 
related to the ocular manifestations in HIV patients with the decrease 
in CD4 count, the immunity decreases and the increase in occurrence 
of opportunistic infections, malignancies and other manifestations in 
HIV patients. 
 In terms of ocular symptoms, majority of patients are 
asymptomatic and only 12 patients (12%) are symptomatic. 
Defective vision being the predominant symptom, patients with 
CMV retinitis and toxoplasmosis are symptomatic with complaints 
 of defective vision and flashes/floaters. HIV microangiography and 
confunctional microvasculopathy patients are asymptomatic. 
 Anterior segment manifestations are seen in 12.96% of 
patients with ocular manifestations. Out of 7, 5 (71.4%) had iritis 
and 2 (28.5%) had Dry eye. 
 Among 5 Iritis affected patients, 3 had posterior segment 
inflammation. One patient had CMV retinitis, one patient had 
Toxoplasmo retinitis and one patient had pan uveitis 2 patients had 
old iritis with festooned pupil.  Thus implies that most of the iritis in 
HIV patients are associated with or “spill over” from posterior 
segment inflammation.  Most of these patients were treated with 
HAART. 
 J. Biswas et al (2008) reported that iritis is rarely associated 
with HIV diseases.  Majority of cases are associated with retinal or 
choroidal infection such as CMV, tomoplasma, TB, syphilis etc. 
 No cases of keratitis are reported in this study. 
 Posterior segment manifestations are reported in 31.48% of 
patients with ocular manifestations. It is the 2nd most common 
manifestation next to adnexal manifestations in this study seen in 
17% of HIV patients. 
  41.17% patients with posterior segment manifestations had 
CD4 count < 100 cells / mm3.  With decrease in CD4 count, the 
incidence of  posterior segment manifestations has increased. 
 HIV microangiography is the most common retinal 
manifestation in this study affecting 10% of patients and 58% among 
patients with ocular manifestations. Cotton wool spots are the most 
common manifestation followed by hemorrhage. 
 Kuppermann BD et al (1993) reported HIV retinopathy in 35% 
of patients. In patients with CD4 count < 50 cells / mm3, 45% had 
HIV retinopathy where as in patients with CD4 count > 50 cells / 
mm3 only 16% had HIV retinopathy. 
 DA Jabs et al (1995) reported HIV retinopathy in 50% of HIV 
patients. 
 But studies in India showed, low prevalence of HIV 
microangiography which correlates well with this study. 
 J. Biswas et al (2000) reported HIV retinopathy in 15% of HIV 
patients. 
 Venkatesh et al (2008) reported the prevalence of HIV 
retinopathy as 11% among patients infected with HIV. 
  In this study, in patients with CD4 count < 100, 21.7% had 
HIV microangiography whereas only 6.7% had HIV micro 
angiography in patients with CD4 count 100-200.  This support the 
literature that when CD4 count decreases the prevalence of HIV 
retinopathy increases. 
 The prevalence of HIV retinopathy has increased with increase 
in age in this study.  6.25% affected in the age group between 20-30, 
9.75% in 31-40 age group and 22.2% in 41-50 age group. 
 Furrer et al (2003) reported that HIV microangiography is 
associated with higher age group and higher viral load of HIV. 
 J Biswas et al (2008) related that the occurrence of HIV micro 
angiography correlates well with the conjunctional 
microvasculopathy.  In the present study, 7 (70%) patients out of 10 
patients with retinal microangiography had conjunctival 
microvasculopathy. 
 Clinical diagnosis of CMV retinitis is made in 4 patients (4%) 
in the total study group and in 23.5% of patients with posterior 
segment manifestations.  Majority of them complained of defective 
vision and floaters. Two of the patients had secondary optic atrophy 
following CMV retinitis. 
  Various literature gives incidence of CMV retinitis as high as 
15-40%. But in this study group, CMV retinitis is reported in only 
4% of total study group and 23.5% of those with posterior segment 
manifestations.  The higher incidence in literature may be because 
the studies elsewhere conducted dealt with full blown cases of 
AIDS, while this study is a mixture of asymptomatic cases with 
fewer cases of AIDS. 
 All the 4 patients with CMV retinitis were on HAART. Only 
one patient had CD4 count < 100 cells / cu.mm.  Other 3 had CD4 
count > 100 cells / cu.mm. 
 Various literature states that with the introduction of HAART, 
the incidence of CMV retinitis has come down approximately by 
75%. But in this study, CMV retinitis is seen in patients treated with 
HAART.  This is explained by Brian et al that CMV retinitis may 
occur with CD4 count > 100 cells / cu mm, because there may be 
incomplete restoration of the immune repertoire against CMV with 
HAART therapy. 
 Toxoplasma retino choroiditis is seen in 1 patient.  It is a 
reactivation of old healed macular scar. The patient had symptoms of 
defective vision and floaters. The CD4 count was 836 cells/cumm.  
 “Spill over” anterior uveitis was also seen.  Serological tests were 
not done due to lack of facility. 
 The panuveitis is seen in 1 patient secondary to TB. The 
patient is treated with ATT and steroids.  ARN, PORN are not 
reported in this study. 
 Ocular adnexal manifestation is seen in 43% of HIV infected 
patients, conjunctival microvasculopathy being the commonest 
manifestation.  
 Conjunctional microvasculopathy is seen in 36% of patients in 
the study and in 83% of patients with adnexal manifestation. 
Literature evidence shows that 70-80% of HIV patients show 
conjunctival microvasculopahty and it correlates with the retinal 
microangiopathy.  19.4% of patients with conjunctival 
microvasculopathy are associated with retinal microangiopathy. 
 Ocular surface squamous neoplasia is seen in 1 patient with 
CD4 count 50 cells / cu mm.  Nodular vascularised mass is seen in 
temporal limbus.  Excision biopsy was done. HPE report confirmed 
low grade verrucous type of squamous cell carcinoma. 
 
 
   HZO is seen in 1 patient. The CD4 count is 345 cells. J. 
Biswas et al reported 1 case in 100 cases of  HIV patients in 1999 & 
7 cases per 100 HIV patients  in 2008. HZO has been reported to 
occur  in all stages of HIV. 
 Other manifestations include ACCO, Allergic conjunctivitis, 
molluscum of the lid, Blepharitis and lacrimal fistula. keratitis is not 
reported in this study. 
 Neuro ophthalmic manifestations are seen in 4% of patients in 
study group and 7.4% of patients with ocular manifestations. 1 
patient had papilloedema with headache, vomiting, probably due to 
increased intracranial hypertension. 1 patient had secondary optic 
atrophy with bilateral LR palsy secondary to crptococcal meningitis.  
AIDS dementia complex was associated with 1 patient with primary 
optic atrophy. LMN type facial N palsy was seen in 1 patient. 
Majority of neuro ophthalmatic manifestations are secondary to CNS 
lesions which is in accordance with literature evidence. 
 Orbital cellulitis is seen in 1 patient (1%) secondary to abscess 
in the lid. 
 
 
  Among 100 patients, 2 patients presented with ocular 
manifestations as their first presentation which led to HIV diagnosis. 
 From the present study, we can conclude that anterior segment 
manifestations occur as often as the posterior segment 
manifestations.  Majority of ocular manifestations are seen in patient 
with CD4 count < 100 cells / cu mm. But vision threatening lesions 
are also seen in patients with CD4 count > 100 cells / cu mm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY 
 
 The present cross sectional study is an attempt to assess the 
frequency of ocular manifestations in HIV infected patients and its 
correlation with CD4 count. 
 The study included 100 patients with 60 males and 40 females 
infected with HIV / AIDS attending ophthalmology outpatient ward 
in Govt Rajaji Hospital or referred from ART centre and other 
departments. 
¾ Ocular manifestations seen in 54 (54%). 
 Among patients with ocular manifestations. 
¾ No. of patients with posterior segment manifestation is 17 
(31.48%) 
¾ No.of patients with anterior segment manifestations is 7 
(12.96%) 
¾ No.of patients with adnexal manifestations is 43 (79.62%) 
¾ No. of patients with neuro ophthalmic manifestations is 4 
(7.4%) 
¾ Majority belong to the age group of 20-40 years (73%) 
¾ Most common systemic infection associated is tuberculosis. 
 ¾ 60.8% of patients and CD4 count < 100 cells / cu mm have 
ocular manifestations. But vision threatening lesions like CMV 
retinitis and toxoplasma retinitis have been reported in patients 
with CD4 count > 100 cells / cu mm in this study. 
¾ HIV microangiography is found to be the most common 
retinal manifestations (10%). It correlates well with the 
occurrence of conjunctival microvasculopathy. 
¾ Comparing the prevalence of retinal manifestations on HIV / 
AIDS with the international literature evidence, the prevalence 
is low. But it correlates with Indian Literature (J.Biswas et al 
and Pradyot Biswas et al). 
 
 
 
 
 
 
 
 
 
                                       CONCLUSION 
 
 Ophthalmic manifestations of HIV disease are increasingly 
being recognized in the present era due to increased longevity of 
patients after HAART. 
 This emphasizes the necessity for early recognition of ocular 
lesions and early treatment to provide good quality of vision, thereby 
providing good quality of life to patients infected with HIV. 
 In this study, sight threatening lesions like CMV retinitis and 
toxoplasma retinitis were reported in patients with CD4 count > 100 
cells / cu mm. 
 Regular Ophthalmic examination must be done preferably 
once in 6 months in patients with CD4 count > 100 cells/ cumm and 
once in 3 months in patients with CD4 count < 50 cells cu mm, since 
the sight threatening lesions can occur at any stage of HIV infection. 
Screening for retinal disease can be done at home by patients 
themselves using Amsler’s grid test once weekly by which they can 
detect scotomas in the central field.  This would favour an early 
diagnosis and treatment, hence better visual prognosis. 
  HIV patients should be educated about the ocular 
manifestations and should be advised to undergo regular ophthalmic 
examinations. 
 Health care professionals should be trained and educated to 
pick up early cases of ophthalmic manifestations of HIV/AIDS 
thereby preventing vision threatening complications. 
 Timely referral for complete ophthalmic examination and early 
institution of therapy should be done to help the cause of people 
living with HIV / AIDS. 
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 PROFORMA  -    HIV RETINOPATHY 
 
IDENTITY NO  :                              AGE:                      
 SEX: 
EDUCATION  :                             OCCUPATION : 
MARITAL STATUS :                             ROUTE OF 
TRANSMISSION: 
HIV TIME OF DIAGNOSIS:                                  
ART DRUGS:                                       DATE  OF STARTING:  
DURATUON: 
IF YES, MISSED DOSES/DEFAULT:        
           HOW MANY TIMES: 
           NO OF DAYS: 
 
OPPORTUNISTIC INFECTIONS:  
VDRL  :                       TB:                        HERPES 
SIMPLEX: 
HERPES ZOSTER:                      CMV:                     PCP: 
TOXOPLASMA : 
OTHERS  : 
PREVIOUS VISIT: 
DATE  : 
 RETINAL FINDINGS: 
 
     INITIAL VISIT        STUDY VISIT 
           CD4 COUNT   
   WHO CLINICAL 
STAGING 
  
 
STUDY VISIT  :                   CD4: 
DATE:                                                   CD4%: 
VISUAL COMPLAINTS:                    CD3: 
                                                              CD3%: 
VN:                                                       ALC: 
AS:                                                      LIDS 
                                                           CONJ 
                                                              CORNEA 
                                                            AC 
                                                           IRIS 
                                                            PUPIL 
                                                           LENS 
PS: 
  
KEY TO MASTER CHART 
SEX: 
   Male – 1, female – 2 
ART TAKING: 
   Yes – 1, no – 2  
AS MANIFESTATIONS: 
   NAD – 1 
Conjunctival microvasculopathy – 2 
   HZO – 3 
   Dry eye – 4  
   OSSN – 5 
   ACCO – 6 
   Vernal conjunctivitis – 8 
   Blepharitis – 9  
   Orbital  cellulites – 10 
   Iritis – 11  
   Lacrimal fistula – 12  
   Molluscum – 13 
 PS MANIFESTATIONS: 
     NAD – 1 
     HIV microangiopathy – 2 
     CMV retinitis – 3  
     Toxoplasma retinitis – 4 
     Old choroiditis scar – 5  
     Panuveitis – 6 
NEURO OPHTHALMIC MANIFESTATIONS: 
     NAD – 1 
     Optic atrophy – 2 
     6th cranial nerne palsy – 3  
     7th cranial nerve palsy – 4  
     Papilloedema – 5  
TB : 
     Yes – 1  
      No - 2    
 
 
 
                                    ABBREVIATIONS 
AIDS        –          Acquired immuno deficiency syndrome 
ARN         -          Acute retinal necrosis 
ART          -          Anti retroviral therapy 
CME        -            Cystoid macular edema 
CMV        -           Cytomegalo virus 
CWS        -            Cotton wool spots 
ELISA      -           Enzyme linked immmunosorbent assay 
HAART  -            Highly activated antiretroviral therapy 
HHV      -              Human herpes virus 
HIV        -              Human immunodeficiency virus 
HSV       -             Herpes simplex virus 
HPV      -             Human papilloma virus 
HZV       -             Herpes zoster virus 
MAC      -            Mycobacterium avium complex 
OSSN    -             Ocular surface squamous neoplasia 
PORN    -              Progressive outer retinal necrosis 
RD         -         Retinal detachment 
TB         -     Tuberculosis 
 
  
 
 
 
 
 
 
                                         CONSENT FORM 
 
           I was informed & explained of the purpose & nature of the 
study. I am willing to participate in this study. I hereby give my full 
consent for the study.                     
                                                                                     
                                                                 Signature of the patient 
 
                                                                   Name of the patient 
 
 
 
 
 
 
  
 
 
HIV VIRUS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
VIRAL REPLICATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
HERPES ZOSTER OPHTHALMICUS            BLEPHARITIS 
 
 
 
 
 
 
 
      MOLLUSCUM OF THE         CONJUNCTIVAL 
         LID                       MICROVASCULOPATHY 
 
 
 
 
 
 
 
  
CONJUNCTIVAL OSSN 
PRE OPERATIVE 
 
 
 
 
 
 
 
 
POST OPERATIVE 
 
 
 
 
 
 
 
 
 
 
 
  
HIV MICRO ANGIOPATHY 
 
 
 
 
 
 
 
 
 
TOXOPLASMA RETINO CHOROIDITIS 
 
 
 
 
 
 
 
 
 
 
  
CMV RETINITIS 
 
 
 
 
 
 
 
GIOD 
 
 
 
 
 
 
 
 
 
 
  
ORBITAL CELLULITIS 
 
 
 
 
 
 
 
 
 
FACIAL NERVE PALSY 
 
 
 
 
 
 
 
 
 
 
 
S.No. op no age sex CD4 CD3 ALC ART RE AS LE AS RE PS LE PS NO TB ASS CONDITIONS
1 415645 27 1 75 2 2 2 1 1 1 1
2 415624 39 1 131 976 1243 2 1 1 1 1 1 2
3 415734 39 1 45 1 5 1 1 1 1 2
4 415827 35 2 136 1124 1584 2 1 1 1 1 1 2
5 415398 26 1 161 1932 2312 2 2 2 1 1 1 1
6 415625 32 1 375 2127 2335 2 1 1 1 1 1 2
7 415892 6 2 455 2824 3815 2 1 1 1 1 1 2
8 415439 21 2 593 3063 3576 2 1 1 1 1 1 2 genital warts
9 415289 25 2 58 1192 1398 2 1 1 1 1 1 2
10 415425 36 2 169 2310 2806 2 2 2 1 1 1 2
11 426749 35 2 155 2 2 2 1 1 1 2
12 416153 29 1 111 1423 1587 2 2 2 1 1 1 1
13 415804 36 1 187 2 1 1 1 1 1 1
14 416337 37 1 190 1380 1966 2 1 1 1 1 1 2
15 416451 39 1 5 183 1 1,4 1,4 1 1 2,3 1 cryptoccal meningitis
16 415382 42 1 816 2157 2605 2 1 11 1 4 1 2
17 527918 42 1 49 1 2 2 2 2 1 2
18 103833 35 2 419 2 1 1 1 1 1 2
19 416753 60 2 210 3723 3953 2 1 1 1 1 1 2
20 417221 35 1 245 2 1 1 1 1 1 2
21 417216 41 1 165 2 1 1 1 1 1 2
22 418142 21 2 316 2 11 11 6 6 1 2
23 419626 35 1 156 2 2 2 2 1 1 2
24 420402 35 1 312 1267 1924 2 2 2 1 1 1 1
25 419925 47 1 1303 3120 4333 2 1 1 2 2 1 2
26 424752 40 1 827 3308 3959 2 2 2,11 1 1 1 2
27 413289 32 1 75 1192 1525 2 1 1 5 1 1 2 oral candida
28 429864 40 1 52 543 715 2 1 1 1 2 1 2
29 428753 24 2 28 1 2 2 1 1 4 2
30 430130 38 1 345 2 10 1 1 1 1 2
31 413526 26 2 260 1269 1 8 8 3 5 1 2
32 413529 34 1 116 598 1 2 2,11 1 3 1 1
33 412356 25 2 442 6434 7061 2 2 2 2 1 1 1
34 432167 31 2 376 2306 2814 2 1 1 1 1 1 2
35 431735 24 1 171 2960 3211 1 1 1 1 1 1 2
36 667/09 24 2 272 1717 2233 2 2 2 1 1 1 2 vulvovaginal candidiasis
37 563/08 45 1 354 2 1 1 1 1 2 1 AIDS dementia complex
38 464/09 38 1 97 1526 1795 1 1 1 1 1 1 1 oral candida
39 431837 37 1 314 2 1 1 1 1 1 2
40 639/09 27 2 195 623 850 2 8 8 1 1 1 2
41 706/09 23 2 1227 2596 3251 2 1 1 1 1 1 2
42 396/09 30 2 168 1398 1859 1 2 2 3 3 1 1
43 1760/08 34 2 249 1698 1895 2 2 2 1 1 1 1
44 01/07art 52 1 86 1019 1165 2 1 1 1 1 1 1
45 3374 37 1 145 2 2 2 1 2 1 2
46 2248/08 10 2 781 2718 3305 2 1 1 1 1 1 2
47 2247/08 7 1 696 2764 3656 2 1 1 1 1 1 2
48 029/09 31 2 37 1209 1 9,12 9,12 1 1 1 2
49 1742/07 29 1 165 2232 2558 2 1 1 1 1 1 1
50 762/09 42 1 116 822 1020 2 1 1 1 1 1 2
51 766/09 42 1 30 691 751 2 1 1 1 1 1 2
52 760/09 36 1 124 1535 1807 1 1 1 1 1 1 2
53 4059 35 1 129 2 1 1 1 1 1 2
54 758/09 47 1 44 855 1246 2 2 2 2 1 1 2 oral candida
55 753/09 37 2 141 1097 1376 2 2 2 1 1 1 2
56 752/09 16 2 167 1288 1559 2 1 1 1 1 1 1
57 770/09 50 2 359 1747 2374 2 1 1 1 1 1 2
58 779/09 45 1 234 2 2 2 1 1 1 2
59 774/09 37 1 191 1394 1613 2 2 2 1 1 1 2
60 752/09 47 2 205 2 2 2 1 1 1 2
61 720/09 37 1 31 741 1353 2 1 1 1 1 1 1 herpes zoster
62 145/08 27 2 52 1 2 2 3 3 1 1 esophagial candidiasis
63 1850/06 40 2 219 1291 1568 1 2 2 1 1 1 2 chicken pox
64 790/09 33 1 275 1112 1559 2 1 1 1 1 1 1
65 820/06 38 1 96 91 1092 2 1 1 1 1 1 1
66 148/08 45 2 159 997 1284 2 1 1 1 1 1 2
67 206/07 30 1 836 2568 33 1 1 1 1 1 5 2
68 483/06 35 2 549 1636 2123 1 1 1 1 1 1 2 oral candida
69 837/05 45 2 70 1022 1392 2 2 2 2 2 1 2 herpes zoster
70 829/08 40 2 288 2 1 1 2 1 1 1 enital molluscum, oral candid
71 725/09 37 1 377 1398 2335 2 1 1 1 1 1 2
72 2203/08 30 2 136 1124 1584 2 2 2 1 1 1 2
73 701/05 35 2 1551 3915 5272 1 11 11 1 1 1 1
74 729/09 25 1 29 1253 1513 2 2 2 1 1 1 2
75 621/09 43 1 166 1101 1268 2 2 2 1 1 1 2
76 734/09 30 1 212 1190 1691 2 1 1 1 1 1 2
77 2147/06 13 1 271 1001 1907 2 1 1 1 1 1 2
78 707/09 26 2 20 275 373 2 1 1 1 1 1 2
79 796/09 51 1 354 2 2 2 1 1 1 2
80 755/09 44 1 59 839 1115 2 2 2 1 1 1 1
81 1730/08 27 1 134 1220 1563 1 2 2 1 1 1 1 genital herpes
82 791/09 40 1 269 1639 1863 2 2 2 1 1 1 2
83 783/09 30 1 70 1604 2004 2 1 1 1 1 1 2
84 1153/07 24 1 433 980 1312 2 6 6 1 1 1 2
85 49192 31 2 256 2 1 1 1 1 1 2
86 826/09 43 1 299 2092 2865 2 2 2 1 1 1 2
87 2069/07 23 2 240 2 1 3 1 1 1 2
88 49773 23 2 142 14 189 2 1 1 1 1 1 2 pancytopenia
89 1306/07 35 1 322 1704 2497 2 4 4 1 1 1 2 genital herpes,oral candida
90 2345 24 1 604 2760 3486 2 1 1 1 1 1 2
91 857/09 28 1 124 1043 1547 2 1 1 1 1 1 2
92 767/09 28 1 205 943 120 1 1 1 1 1 1 2
93 873/09 30 2 47 473 600 2 2 2 2 2 1 2
94 2089/07 29 2 137 680 1157 2 2 2 1 1 1 2
95 884/08 13 2 299 3471 4357 2 1 1 1 1 1 2
96 885 42 2 62 565 762 2 1 1 1 1 1 1 herpes  
97 652/09 40 1 303 1718 1917 2 1 1 1 1 1 2
98 876/09 33 1 199 1369 1802 2 2 2 1 1 1 2
99 878/09 43 1 303 1718 1917 2 1 1 1 1 1 2
100 840 25 1 231 2 2,13 2 1 1 1 2
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